Predictors of uterine fibroid volume reduction under ulipristal acetate: a prospective MRI study.


Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 22 01 2019
revised: 31 05 2019
accepted: 11 07 2019
pubmed: 9 10 2019
medline: 20 9 2020
entrez: 10 10 2019
Statut: ppublish

Résumé

Can patient and/or uterine fibroid characteristics predict the volume reduction of fibroids under ulipristal acetate (UPA) treatment? This was a monocentric observational prospective cohort study of women with symptomatic fibroids who were willing to undergo surgery after a 3-month treatment of daily 5 mg doses of UPA. Patients underwent magnetic resonance imaging before and after treatment, and the volumes of the three largest fibroids were assessed. The reduction in volume was assessed qualitatively: fibroids decreasing in volume were considered to be 'responsive' to treatment, and fibroids that were stable or increased in volume were considered to be 'non-responsive'. Comparisons were made of patient (age and body mass index) and fibroid (initial volume, number and location) characteristics between fibroids that were responsive and non-responsive to UPA treatment. Fifty-three women were included in the final analysis and 116 fibroids were measured. The initial number and initial volume of the fibroids were statistically associated with the response to UPA treatment (adjusted odds ratio [OR] 0.645, 95% confidence interval [CI] 0.461-0.903, P = 0.0115 for number of fibroids, and adjusted OR 1.447, 95% CI 1.063-1.970, P = 0.0195 for initial volume, with a log-linear relationship). Submucosal fibroids had a higher response rate to treatment (i.e. a decrease in volume) than intramural fibroids (21/25 [84.0%] versus 15/28 [53.6%]; P = 0.0490; adjusted OR 4.478, 95% CI 1.007-19.918). The location, initial volume and number of fibroids may allow prediction of the outcome of a single 3-month treatment course of daily 5 mg doses of UPA in terms of reduction in volume before surgery.

Identifiants

pubmed: 31594689
pii: S1472-6483(19)30661-3
doi: 10.1016/j.rbmo.2019.07.028
pii:
doi:

Substances chimiques

Norpregnadienes 0
ulipristal acetate YF7V70N02B

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

795-801

Informations de copyright

Copyright © 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Auteurs

Antoine Netter (A)

Department of Obstetrics and Gynecology, Assistance Publique Hôpitaux de Marseille, La Conception Hospital, Aix Marseille University, France. Electronic address: antoine.netter@gmail.com.

Vanessa Pauly (V)

Department of Public Health and Medical Information, Assistance Publique Hôpitaux de Marseille, La Conception Hospital, Aix Marseille University, France; Aix Marseille University, School of Medicine - La Timone Medical Campus, CEReSS - Health Service Research and Quality of Life Center, Marseille, France.

Pascale Siles (P)

Department of Women Health Imaging, Assistance Publique Hôpitaux de Marseille, La Timone Hospital, Aix Marseille University, France.

Audrey Pivano (A)

Department of Obstetrics and Gynecology, Assistance Publique Hôpitaux de Marseille, La Conception Hospital, Aix Marseille University, France.

Vincent Vidal (V)

Department of Medical Imaging, Assistance Publique Hôpitaux de Marseille, La Timone Hospital, Aix Marseille University, France.

Aubert Agostini (A)

Department of Obstetrics and Gynecology, Assistance Publique Hôpitaux de Marseille, La Conception Hospital, Aix Marseille University, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH